Conway A; Valerio H; Peacock A; Degenhardt L; Hayllar J; Harrod ME; Henderson C; Read P; Gilliver R; Christmass M; Dunlop A; Montebello M; Whitton G; Reid D; Lam T; Alavi M; Silk D; Marshall AD; Treloar C; Dore GJ; Grebely J, 2021, 'Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study', International Journal of Drug Policy, vol. 96, pp. 103421, http://dx.doi.org/10.1016/j.drugpo.2021.103421
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J, 2021, 'Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study', Clinical Infectious Diseases, vol. 73, pp. E69 - E78, http://dx.doi.org/10.1093/cid/ciaa571
Grebely J; Catlett B; Jayasinghe I; Valerio H; Hajarizadeh B; Verich A; Cunningham P; Martinello M; Tillakeratne S; Silk D; Dore GJ; Applegate TL, 2020, 'Time to Detection of Hepatitis C Virus Infection with the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis', Journal of Infectious Diseases, vol. 221, pp. 2043 - 2049, http://dx.doi.org/10.1093/infdis/jiaa037
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Alberto Arnaiz J; Cooper D; Rockstroh JK; Mallon P; Emery S; Fisher M; Rockstroh J; Stellbrink J; Merlin K; Yeung J; Fsadni B; Marks K; Suzuki K; Rismanto N; Salomon H; Rubio AE; Chibo D; Birch C; Swenson L; Chan D; Berg T; Obermeier M; Schuelter E; Aragon SS; Luebke N; Coughlan S; Dean J; Iwatani Y; Teran GR; Avila S; Sirivichayakul S; Naphassanant M; Ubolyam S; Kaye S; Land S; Walker S; Haubrich R; DeJesus E; Berthon-Jones N; Espinosa N; Courtney-Vega K; Absar N; Haskelberg H; Robson R; Donaldson A; Guelman D; Gambardella L; Valdovinos M; Arnaiz J; Beleta H; Ramos N; Targa M; Späth B; Boesecke C; Engelhardt A; Perry N; Beckthold B; Drummond F; Lefevre E; Corr S; Grant C; Lupo S; Peroni L; Sanchez M; De Paz Sierra M; Viloria G; Parlante A; Bissio E; Luchetti P; Confalonieri V; Warley E; Vieni I; Vilas C; Zarate A; Mayer G; Elliot J; Hagenauer M; Kelley M, 2018, 'Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study', HIV Medicine, vol. 19, pp. 65 - 71, http://dx.doi.org/10.1111/hiv.12532
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S, 2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus ritonavir-boosted protease inhibitor regimen: Week 48 Results of the randomized, multicenter March study', Clinical Infectious Diseases, vol. 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207
